vs
Amphastar Pharmaceuticals, Inc.（AMPH）とTaskUs, Inc.（TASK）の財務データ比較。上の社名をクリックして会社を切り替えられます
TaskUs, Inc.の直近四半期売上が大きい（$313.0M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.7倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 9.5%、差は3.8%）。TaskUs, Inc.の前年同期比売上増加率が高い（14.1% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $9.9M）。過去8四半期でTaskUs, Inc.の売上複合成長率が高い（17.3% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
CTG（Computer Task Group）は米国ニューヨーク州バッファロー本社の多国籍企業で、情報技術分野の人材配置サービスを提供しています。2023年12月、Cegekaが同社の74%に達する過半数株式の買収を完了したことが発表されました。
AMPH vs TASK — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $313.0M |
| 純利益 | $24.4M | $29.7M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 12.2% |
| 純利益率 | 13.3% | 9.5% |
| 売上前年比 | -1.8% | 14.1% |
| 純利益前年比 | -35.7% | 235.3% |
| EPS（希薄化後） | $0.51 | $0.31 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $313.0M | ||
| Q3 25 | $191.8M | $298.7M | ||
| Q2 25 | $174.4M | $294.1M | ||
| Q1 25 | $170.5M | $277.8M | ||
| Q4 24 | $186.5M | $274.2M | ||
| Q3 24 | $191.2M | $255.3M | ||
| Q2 24 | $182.4M | $237.9M | ||
| Q1 24 | $171.8M | $227.5M |
| Q4 25 | $24.4M | $29.7M | ||
| Q3 25 | $17.4M | $31.4M | ||
| Q2 25 | $31.0M | $20.0M | ||
| Q1 25 | $25.3M | $21.1M | ||
| Q4 24 | $38.0M | $8.9M | ||
| Q3 24 | $40.4M | $12.7M | ||
| Q2 24 | $37.9M | $12.6M | ||
| Q1 24 | $43.2M | $11.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 12.2% | ||
| Q3 25 | 13.2% | 12.7% | ||
| Q2 25 | 24.2% | 10.3% | ||
| Q1 25 | 21.9% | 12.3% | ||
| Q4 24 | 24.2% | 8.0% | ||
| Q3 24 | 29.8% | 9.5% | ||
| Q2 24 | 30.3% | 9.5% | ||
| Q1 24 | 27.9% | 10.4% |
| Q4 25 | 13.3% | 9.5% | ||
| Q3 25 | 9.0% | 10.5% | ||
| Q2 25 | 17.8% | 6.8% | ||
| Q1 25 | 14.8% | 7.6% | ||
| Q4 24 | 20.4% | 3.2% | ||
| Q3 24 | 21.1% | 5.0% | ||
| Q2 24 | 20.8% | 5.3% | ||
| Q1 24 | 25.1% | 5.1% |
| Q4 25 | $0.51 | $0.31 | ||
| Q3 25 | $0.37 | $0.34 | ||
| Q2 25 | $0.64 | $0.22 | ||
| Q1 25 | $0.51 | $0.23 | ||
| Q4 24 | $0.74 | $0.09 | ||
| Q3 24 | $0.78 | $0.14 | ||
| Q2 24 | $0.73 | $0.14 | ||
| Q1 24 | $0.81 | $0.13 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $211.7M |
| 総負債低いほど良い | $608.7M | $241.4M |
| 株主資本純資産 | $788.8M | $600.0M |
| 総資産 | $1.6B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.40× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $211.7M | ||
| Q3 25 | $276.2M | $210.0M | ||
| Q2 25 | $231.8M | $181.9M | ||
| Q1 25 | $236.9M | $196.9M | ||
| Q4 24 | $221.6M | $192.2M | ||
| Q3 24 | $250.5M | $180.4M | ||
| Q2 24 | $217.8M | $171.1M | ||
| Q1 24 | $289.6M | $165.3M |
| Q4 25 | $608.7M | $241.4M | ||
| Q3 25 | $608.6M | $246.3M | ||
| Q2 25 | $607.7M | $249.6M | ||
| Q1 25 | $603.9M | $252.9M | ||
| Q4 24 | $601.6M | $256.2M | ||
| Q3 24 | $596.4M | $259.4M | ||
| Q2 24 | $586.9M | $261.0M | ||
| Q1 24 | $594.0M | $262.6M |
| Q4 25 | $788.8M | $600.0M | ||
| Q3 25 | $776.7M | $567.5M | ||
| Q2 25 | $757.5M | $544.5M | ||
| Q1 25 | $751.3M | $520.3M | ||
| Q4 24 | $732.3M | $496.9M | ||
| Q3 24 | $727.7M | $489.8M | ||
| Q2 24 | $713.3M | $460.2M | ||
| Q1 24 | $672.4M | $454.6M |
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $1.6B | $1.0B | ||
| Q1 25 | $1.6B | $985.5M | ||
| Q4 24 | $1.6B | $953.3M | ||
| Q3 24 | $1.5B | $942.1M | ||
| Q2 24 | $1.5B | $886.1M | ||
| Q1 24 | $1.6B | $874.5M |
| Q4 25 | 0.77× | 0.40× | ||
| Q3 25 | 0.78× | 0.43× | ||
| Q2 25 | 0.80× | 0.46× | ||
| Q1 25 | 0.80× | 0.49× | ||
| Q4 24 | 0.82× | 0.52× | ||
| Q3 24 | 0.82× | 0.53× | ||
| Q2 24 | 0.82× | 0.57× | ||
| Q1 24 | 0.88× | 0.58× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $29.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $9.9M |
| FCFマージンFCF / 売上 | 13.4% | 3.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | 6.3% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 1.00× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $73.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $29.7M | ||
| Q3 25 | $52.6M | $54.3M | ||
| Q2 25 | $35.6M | $17.0M | ||
| Q1 25 | $35.1M | $36.3M | ||
| Q4 24 | $29.0M | $40.7M | ||
| Q3 24 | $60.0M | $17.0M | ||
| Q2 24 | $69.1M | $30.0M | ||
| Q1 24 | $55.3M | $51.2M |
| Q4 25 | $24.6M | $9.9M | ||
| Q3 25 | $47.2M | $42.0M | ||
| Q2 25 | $25.0M | $38.0K | ||
| Q1 25 | $24.4M | $21.8M | ||
| Q4 24 | $16.6M | $20.4M | ||
| Q3 24 | $46.2M | $6.3M | ||
| Q2 24 | $63.1M | $25.5M | ||
| Q1 24 | $46.5M | $47.6M |
| Q4 25 | 13.4% | 3.2% | ||
| Q3 25 | 24.6% | 14.0% | ||
| Q2 25 | 14.3% | 0.0% | ||
| Q1 25 | 14.3% | 7.8% | ||
| Q4 24 | 8.9% | 7.4% | ||
| Q3 24 | 24.1% | 2.5% | ||
| Q2 24 | 34.6% | 10.7% | ||
| Q1 24 | 27.1% | 20.9% |
| Q4 25 | 4.5% | 6.3% | ||
| Q3 25 | 2.8% | 4.1% | ||
| Q2 25 | 6.1% | 5.8% | ||
| Q1 25 | 6.3% | 5.2% | ||
| Q4 24 | 6.7% | 7.4% | ||
| Q3 24 | 7.2% | 4.2% | ||
| Q2 24 | 3.3% | 1.9% | ||
| Q1 24 | 5.1% | 1.6% |
| Q4 25 | 1.35× | 1.00× | ||
| Q3 25 | 3.03× | 1.73× | ||
| Q2 25 | 1.15× | 0.85× | ||
| Q1 25 | 1.39× | 1.72× | ||
| Q4 24 | 0.76× | 4.59× | ||
| Q3 24 | 1.48× | 1.34× | ||
| Q2 24 | 1.82× | 2.38× | ||
| Q1 24 | 1.28× | 4.37× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TASK
| Digital Customer Experience | $172.7M | 55% |
| Trust And Safety | $82.7M | 26% |
| AI Services | $57.5M | 18% |
